SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Takeda Pharmaceutical Company Limited TKPHF OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • JP • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Takeda Pharmaceutical Company Limited (TKPHF) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $34.52. It has a SharesGrow Score of 67/100, indicating a above average investment profile with 4 out of 7 criteria passed.

Financials: revenue is $4.6T, +8.7%/yr average growth. Net income is $107.9B, growing at -13.9%/yr. Net profit margin is 2.4% (thin). Gross margin is 65.5% (-3.5 pp trend).

Balance sheet: total debt is $4.5T against $6.9T equity (Debt-to-Equity (D/E) ratio 0.65, moderate). Current ratio is 1.01 (adequate). Debt-to-assets is 31.7%. Total assets: $14.2T.

Analyst outlook: 4 / 5 analysts rate TKPHF as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 40/100 (Partial), Past 100/100 (Pass), Health 33/100 (Fail), Moat 79/100 (Pass), Future 90/100 (Pass), Income 30/100 (Fail).

TKPHF SharesGrow Score Overview

67/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 100/100

Valuation — P/E, PEG, Forward PEG

GROWTH 40/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 33/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 79/100

Gross margin is + market cap

FUTURE 90/100

Analyst outlook — as buy

INCOME 30/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TKPHF

TKPHF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

TKPHF: +8.7%/yr revenue is, -13.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

TKPHF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet TKPHF: Debt-to-Equity (D/E) ratio 0.65 (moderate), Current ratio is 1.01 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

TKPHF: Gross margin is 65.5% (-3.5 pp trend), $55B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 79/100. ≥ 70 = Pass.

View details →

Analyst outlook: 4 / 5 analysts rate TKPHF as buy (80%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

TKPHF: Net profit margin is 2.4%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range26.1-39.2

Volume500

Avg Volume (30D)14.31K

Market Cap$54.53B

Beta (1Y)0.13

Dividend Yield$1.1715

Share Statistics

EPS (TTM)68.36

Shares Outstanding$1.58B

IPO Date2008-06-25

Employees49,281

CEOChristophe Weber

Financial Highlights & Ratios

Revenue (TTM)$4.58T

Gross Profit$3T

EBITDA$1.07T

Net Income$107.93B

Operating Income$342.59B

Total Cash$405.59B

Total Debt$4.52T

Net Debt$4.13T

Total Assets$14.25T

Price / Earnings (P/E)0.5

Price / Sales (P/S)0.01

Analyst Forecast

Rating ConsensusBuy

Analysts Covering5

Buy 80% Hold 20% Sell 0%

Company Info

CountryJP

ExchangeOther OTC

CurrencyUSD

ISINJP3463000004

Price Chart

TKPHF

Takeda Pharmaceutical Company Limited ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

26.10 52WK RANGE 39.20

People Also View

Chugai Pharmaceutical Co., Ltd.

MERCK Kommanditgesellschaft auf Aktien

Daiichi Sankyo Company, Limited

Astellas Pharma Inc.

Eli Lilly and Company

Johnson & Johnson

Roche Holding AG

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message